Thryv Therapeutics to Present at Evercore ISI 2024 Emerging Biotech Conference

    --  Thryv Therapeutics to present virtually at Evercore ISI 2024 Emerging
        Biotech Conference on Wednesday, February 28(th) from 2:15-2:45 p.m. ET.

MONTREAL, Feb. 20, 2024 /PRNewswire/ - Thryv Therapeutics is pleased to announce its selection as a featured presenter at the Evercore ISI 2024 Emerging Biotech Conference that is taking place virtually on February 28(th) and 29(th), 2024. Thryv's virtual presentation will be on February 28(th) from 2:15-2:45 p.m. ET.

Thryv Therapeutics Inc. (previously LQT Therapeutics Inc.) is a privately owned company based in Montreal, Quebec, Canada. Thryv Therapeutics is pioneering a precision medicine approach to treat indications including Congenital Long QT Syndromes (LQTS), atrial fibrillation and heart failure with potent and selective inhibitors of Serum Glucocorticoid inducible Kinase (SGK1). For more information, please visit www.thryvtrx.com.

SOURCE Thryv Therapeutics Inc.